Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS
Open Access

Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans

Jeremy D. Waight, Shinji Takai, Bo Marelli, Guozhong Qin, Kenneth W. Hance, Dong Zhang, Robert Tighe, Yan Lan, Kin-Ming Lo, Helen Sabzevari, Robert Hofmeister and Nicholas S. Wilson
J Immunol February 1, 2015, 194 (3) 878-882; DOI: https://doi.org/10.4049/jimmunol.1402725
Jeremy D. Waight
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinji Takai
†Oncology Section, Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka 541-8564, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Marelli
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guozhong Qin
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth W. Hance
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dong Zhang
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Tighe
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Lan
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kin-Ming Lo
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Sabzevari
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Hofmeister
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas S. Wilson
*Immuno-Oncology Platform, EMD Serono Research and Development Institute, Billerica, MA 01821;
‡Now Cancer Immunology Group, Agenus, Lexington, MA 02421
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Intratumoral Tregs from several mouse tumor models exhibit Foxp3 stability. (A) CpG methylation analysis of Foxp3, CTLA-4, TNFRSF18, and Ikzf4 from Tconvs and Tregs isolated from the indicated tissue of CT26 tumor-bearing and control mice (pooled, n = 5 mice). (B) Foxp3 TSDR methylation analysis of Tconvs and Tregs from LLC, 4T1, MC-38, MCA-induced tumors (pooled, n = 5 mice). Color coding represents percentage methylation. (C) Tconvs (Foxp3EGFP−) or nTregs (Foxp3EGFP+) were cultured under iTreg (+TGF-β) or Th0 conditions (−TGF-β) for 3 d. Th0, iTregs, and nTregs were incubated in fresh culture media for an additional 2 d (day 5), then analyzed for Foxp3 expression (profiles from n = 5 spleens). The percentage of cells expressing Foxp3 is relative to freshly isolated Tconvs (upper right of histogram). (D) Ex vivo differentiation schematic for cells cultured with TGF-β (iTreg) or without TGF-β (iTreg-to-Tconv, “Reversion”). (E and F) Representative histograms showing the percent of T cells expressing Foxp3 after 5 days of ex vivo culture. Tconvs and Tregs were isolated from spleens and tumors of 4T1 (E) or LLC (F) tumor-bearing mice and subjected to culture conditions outlined in (D). Samples were pooled from n = 5 mice for each model. Tumors were collected when volumes reached 500 mm3. All data are representative of two or more individual experiments.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    TGF-β neutralization does not impact intratumoral Treg accumulation. (A) 4T1 tumor-bearing mice (350–500 mm3) were treated i.v. with 492 μg TGF-β–Trap (n = 10) or isotype control (n = 8) on days 21 and 24 postimplantation (▴). Tissue was harvested on day 26 (△) for serum, phenotype, and methylation analysis. (B) Free active TGF-β in the serum of TGF-β–Trap or isotype-treated 4T1 tumor-bearing mice (n = 5 mice/group). (C) Percentage of Tconvs and Tregs, relative to the total CD4+ T cell population in TGF-β–Trap or isotype-treated mice. Each symbol represents an individual animal (n = 8–10/group). (D) CpG methylation analysis of Foxp3, CTLA-4, TNFRSF18, and Ikzf4 from Tconvs and Tregs isolated from the indicated tissues. Color coding represents percentage methylation. All data are representative of two or more independent experiments. Data are mean ± SEM. *p < 0.05, ***p < 0.001 calculated using Student t test. ns, nonsignificant.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Human intratumoral Tregs have a hypomethylated FOXP3 TSDR profile. (A) CpG methylation analysis of the FOXP3 TSDR in Tconvs (CD3+ CD4+ CD127+ CD25low FOXP3−) and Tregs (CD3+ CD4+ CD25high CD127− FOXP3+) from the peripheral blood of healthy donors (n = 4). (B) FOXP3 TSDR methylation of intratumoral Tconvs and Tregs from NSCLC (n = 4) and ovarian cancer patients (n = 2). Color coding represents percentage methylation.

Additional Files

  • Figures
  • Data Supplement

    Files in this Data Supplement:

    • Supplemental Figures 1 (PDF)
PreviousNext
Back to top

In this issue

The Journal of Immunology: 194 (3)
The Journal of Immunology
Vol. 194, Issue 3
1 Feb 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans
Jeremy D. Waight, Shinji Takai, Bo Marelli, Guozhong Qin, Kenneth W. Hance, Dong Zhang, Robert Tighe, Yan Lan, Kin-Ming Lo, Helen Sabzevari, Robert Hofmeister, Nicholas S. Wilson
The Journal of Immunology February 1, 2015, 194 (3) 878-882; DOI: 10.4049/jimmunol.1402725

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans
Jeremy D. Waight, Shinji Takai, Bo Marelli, Guozhong Qin, Kenneth W. Hance, Dong Zhang, Robert Tighe, Yan Lan, Kin-Ming Lo, Helen Sabzevari, Robert Hofmeister, Nicholas S. Wilson
The Journal of Immunology February 1, 2015, 194 (3) 878-882; DOI: 10.4049/jimmunol.1402725
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil
  • Cutting Edge: T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved
  • Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout Mice
Show more CUTTING EDGE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606